• Subscribe

Just A Huge Video Part 2

You need Flash player 9+ and JavaScript enabled to view this video.
Get Adobe Flash player
Views: Bookmarks: Favorites Twitter Google Bookmarks Yahoo Bookmarks Delicious stumbleupon MySpace Facebook (More)
Send a friend Send to Yahoo Report Abuse
URL:
Embed to website/blog:
Comments

blog comments powered by Disqus
 
 
Just A Huge Video Part 2

From: dawgfan24348

Date: 11/20/2009
Category: Sports

More info

Smaller just part 2 of my huge video Please do research on PKU more info at www.pkunews....

Uga passed away made a video on that already In this video Uga VII Awsers to Hershel Talker's questions Recaps and Previews In Part 2 Going Around My Room What I will do after football season
I found out that I also have Ciliacs autoimmune disease along with PKU
Keywords: PKU
Fo all ya kid out dur, dis jus a lil' vid talkin' bout da impotance of PKU.
I have PKU, and Im sharing some things about food ideas, Kuvan, and suplement.
Keywords: PKU
Since it was so dark decided to redo it PKU News www.pkunews.org
ich liebe dieses lied
Keywords: R&b

momay tbs

Views: 118
From: pipoy1026


pku
Keywords: Movie
FDA has approved the first drug to treat phenylketonuria (PKU), which is a genetic disorder that affects one in about 15 thousand births in the US The drug, called Kuvan (sapropterin dihydrochloride) was developed by BioMarin Pharmaceutical in partnership with Merck. Those with PKU cannot metabolize phenylalanine, which is an amino acid found naturally in many foods. Normally, phenylalanine metabolism is controlled by the enzyme phenylalanine hydroxylase. In PKU patients, this enzyme does not function properly. That causes high blood levels of phenylalanine, which can lead to mental retardation, behavioral abnormalities, seizures and other neurological complications. Kuvan increases the activity of phenylalanine hydroxylase in those PKU patients who have some residual functioning of this enzyme. This leads to improved breakdown and lower blood levels of phenylalanine. Still, in order for the drug to be most effective, patients on Kuvan must be on a phenylalanine-restricted diet, and blood levels must be monitored frequently. The safety and efficacy of Kuvan was demonstrated in four short-term studies of 579 PKU patients. In addition, the manufacturer will establish general disease registries for PKU to help track clinical results and monitor any adverse effects. Additional Information: FDA Press Release. FDA Approves Kuvan for Treatment of Phenylketonuria (PKU). December 13, 2007. www.fda.gov

Copyright © 2010 TheTVnet
eXTReMe Tracker